Asset Dedication’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $49.8K | Sell |
1,314
-610
| -32% | -$28.1K | ﹤0.01% | 497 |
|
|
2026
Q2 | $92.2K | Buy |
1,924
+319
| +20% | +$13.7K | 0.01% | 415 |
|
|
2026
Q1 | $59K | Sell |
1,605
-150
| -9% | -$7.11K | ﹤0.01% | 457 |
|
|
2025
Q4 | $89.3K | Sell |
1,755
-610
| -26% | -$31.2K | 0.01% | 410 |
|
|
2025
Q3 | $131K | Hold |
2,365
| – | – | 0.01% | 387 |
|
|
2025
Q2 | $163K | Sell |
2,365
-12
| -0.5% | -$816 | 0.01% | 351 |
|
|
2025
Q1 | $165K | Buy |
2,377
+12
| +0.5% | +$991 | 0.01% | 317 |
|
|
2024
Q4 | $203K | Buy |
2,365
+11
| +0.5% | +$1.19K | 0.02% | 297 |
|
|
2024
Q3 | $280K | Buy |
2,354
+440
| +23% | +$58.7K | 0.02% | 285 |
|
|
2024
Q2 | $273K | Hold |
1,914
| – | – | 0.02% | 288 |
|
|
2024
Q1 | $246K | Hold |
1,914
| – | – | 0.02% | 280 |
|
|
2023
Q4 | $198K | Hold |
1,914
| – | – | 0.02% | 295 |
|
|
2023
Q3 | $174K | Sell |
1,914
-800
| -29% | -$70.5K | 0.01% | 305 |
|
|
2023
Q2 | $219K | Buy |
2,714
+800
| +42% | +$65.4K | 0.02% | 290 |
|
|
2023
Q1 | $151K | Hold |
1,914
| – | – | 0.01% | 325 |
|
|
2022
Q4 | $129K | Hold |
1,914
| – | – | 0.01% | 342 |
|
|
2022
Q3 | $96K | Buy |
+1,914
| New | +$103K | 0.01% | 346 |
|
|
2022
Q2 | – | Sell |
-1,914
| Closed | -$106K | – | 818 |
|
|
2022
Q1 | $106K | Hold |
1,914
| – | – | 0.01% | 349 |
|
|
2021
Q4 | $107K | Hold |
1,914
| – | – | 0.01% | 323 |
|
|
2021
Q3 | $91K | Buy |
1,914
+320
| +20% | +$15.5K | 0.01% | 331 |
|
|
2021
Q2 | $67K | Buy |
1,594
+76
| +5% | +$2.95K | 0.01% | 354 |
|
|
2021
Q1 | $51K | Buy |
1,518
+1,442
| +1,897% | +$51.4K | 0.01% | 331 |
|
|
2020
Q4 | $3K | Hold |
76
| – | – | ﹤0.01% | 678 |
|
|
2020
Q3 | $3K | Buy |
+76
| New | +$2.53K | ﹤0.01% | 646 |
|
|
2018
Q3 | – | Sell |
-2
| Closed | – | – | 731 |
|
|
2018
Q2 | $0 | Buy |
+2
| New | +$48 | ﹤0.01% | 709 |
|
|
2017
Q1 | – | Sell |
-594
| Closed | -$11K | – | 388 |
|
|
2016
Q4 | $11K | Sell |
594
-576
| -49% | -$10.4K | 0.01% | 296 |
|
|
2016
Q3 | $24K | Sell |
1,170
-1,414
| -55% | -$35.1K | 0.02% | 238 |
|
|
2016
Q2 | $69K | Hold |
2,584
| – | – | 0.05% | 173 |
|
|
2016
Q1 | $70K | Sell |
2,584
-1,380
| -35% | -$37K | 0.05% | 161 |
|
|
2015
Q4 | $115K | Buy |
+3,964
| New | +$110K | 0.08% | 171 |
|
Other funds holding NVO
Asset Dedication's NVO Position: Q3 2026 in Review
Asset Dedication reduced its Novo Nordisk (NVO) stake by 32% in Q3 2026, selling an estimated $28.1K and leaving 1,314 shares worth $49.8K. The position accounts for ﹤0.01% of the portfolio, ranked #497.
Asset Dedication first reported a position in NVO in Q4 2015 and has held it in 30 quarters since. The position peaked at $280K in Q3 2024. 1,061 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- Asset Dedication held 1,314 shares of Novo Nordisk worth $49.8K as of Q3 2026.
- Asset Dedication sold 610 Novo Nordisk shares in Q3 2026, an estimated $28.1K.
- Novo Nordisk made up ﹤0.01% of Asset Dedication's portfolio in Q3 2026, its #497 holding.
- Asset Dedication first reported a position in Novo Nordisk in Q4 2015 and has held it in 30 quarters since.
- Asset Dedication's Novo Nordisk position peaked at $280K in Q3 2024.
- 1,061 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on Asset Dedication's 13F filing for Q3 2026, filed 3 Nov 2026.